title: Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
abstract: It has been suggested that human papillomavirus (HPV) could participate in the development of non-small-cell lung cancer (NSCLC). A higher HPV infection rate has been reported in the NSCLC samples from Asian non-smoker patients, with adenocarcinomas or responders to EGFR tyrosine kinase inhibitors (EGFR-TKI). We explored a potential relationship between EGFR mutation, response to EGFR-TKI and HPV infection in Western NSCLC patients. We retrospectively analyzed 40 NSCLC samples and the impact of age, gender, histology, tobacco habit and sample type. HPV infection rate was 2.5% and it was not statistically modified by any analyzed variable, although the limited sample size did not provide definitive conclusions. The rate of HPV infection in NSCLC should be studied in patients with EGFR mutations or a tendency towards presenting them.
authors.affiliation: Servicio de Oncología Médica, Hospital Universitario Arnau de Vilanova, Lleida, España. dmarmed@hotmail.com
authors.forename: Diego
authors.initials: D
authors.lastname: Márquez-Medina
authors.forename: Ariadna
authors.initials: A
authors.lastname: Gasol-Cudós
authors.forename: M Teresa
authors.initials: MT
authors.lastname: Taberner-Bonastre
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Samamé Pérez-Vargas
authors.forename: Antonieta
authors.initials: A
authors.lastname: Salud-Salvia
authors.forename: Antonio
authors.initials: A
authors.lastname: Llombart-Cussac
mesh_terms: D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics / Q000821:virology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics* / Q000821:virology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics / Q000821:virology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005260:Female; D018773:Genes, erbB-1; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D030361:Papillomavirus Infections / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*; D015995:Prevalence; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D012907:Smoking / Q000453:epidemiology; D013030:Spain / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors